1[1]Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444. patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet, 1994; 344(8934):1383～1389
2[2]Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. New Engl J Med, 1996; 335(14): 1001～1009
3[3]The Long - term Intervention with Pravastatin in Ischemic Disese (LIPID) Study Group. Prevention of cardiovsscular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. New Engl J Med, 1998; 339(19): 1349～1357
5[5]Fonarow GC, Gawlinski A. Rationale and design of the Cardiac Hospitalization Atherosclerosis Management Prograrm. at the University of California Los Angeles. Am J Cardiol, 2000; 85(3A): 10A～17A
6[6]Fonarow GC, Gawlinski A, Moughrabi S, et al. Improved treatment of coronary heart disease by implenentation of a cardiac hospitalization atherosclerosis management progeam (CHAMP). Am J Cardiol, 2001; 87(7):819～822
7[7]Waters DD, Hsue PY. What is the role of intensive cholesterol lowering in the treatment of acute coronary syndromes? Am J Cardiol, 2001; 88(suppl):7J～16J
8[8]Waters D. Cholesterol lowering: should it continue to be the last thing we do? Circulation, 1999; 99(25) :3215～3217
9[9]Gould KL, Martucci JP, Goldberg DI, et al. Short - term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease: a potential noninvasive marker of healing coronary endothelium.Circulation, 1994; 89(4): 1530～1538
10[10]O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-c o enzyme A reductase inhibitor, improves endothelial function within 1 nonth. Circulation, 1997; 95(5):1126～1131
